


**Canadian reference labels for Sotrovimab inner vial and outer carton, with extracted text in ENGLISH**

**Canadian labelled supply**

**Inner label**



**Inner label**

DIN 02518341  
Pr **Sotrovimab** for injection  
**500 mg / 8 mL**  
**(62.5 mg / mL)**

Single-use  
**Dilute before I.V. infusion.**  
Dosage / Administration :  
[www.sotrovimabinfo.com](http://www.sotrovimabinfo.com)  
GSK

LOT XXXXXXXX  
EXP MM-YYYY

**Canadian labelled supply**

**Outer label**

IMMUNOGLOBULINE SPÉCIFIQUE : anticorps monoclonal IgG1 anti-SPAS-CoV-2  
**Ingédients non médicinaux :** L-histidine, monochlorhydrate de L-histidine, saccharose, L-méthionine, polysorbate et eau pour injection. Sans agent de conservation.  
**Entreposage :** Réfrigérer (entre 2 et 8 °C) dans l'emballage d'origine pour protéger le produit de la lumière. NE PAS congeler ni secouer. Garder hors de la portée et de la vue des enfants.  
**Posologie et administration :** Consulter la monographie.  
**SANTÉ CANADA A AUTORISÉ LA VENTE DE CETTE DROGUE LIÉE À LA COVID-19 SUR LA BASE D'ESSAIS CLINIQUES RESTREINTS CHEZ L'ÊTRE HUMAIN ET/OU D'INFORMATIONS SUR LA QUALITÉ.**

DIN 02518341

**Sotrovimab**

Questions / Concerns / Problèmes?  
**GlaxoSmithKline Inc.**  
 Mississauga, Ontario L5N 6L4  
[www.gsk.ca](http://www.gsk.ca)

1 Flacon

Sterile

500 mg / 8 mL

**Sotrovimab**

**pour injection**

(62,5 mg / mL)

Solution pour perfusion intraveineuse

Diluer avant usage.  
 Flacon uniservice. Jeter toute portion inutilisée.  
 Pour consulter la version actuelle de la monographie, balayer le code QR ou accéder à [www.sotrovimabinfo.com](http://www.sotrovimabinfo.com).

HEALTH CANADA HAS AUTHORIZED THE SALE OF THIS COVID-19 DRUG BASED ON LIMITED CLINICAL TESTING IN HUMANS AND/OR QUALITY INFORMATION.

**Dosage and administration:** See Product Monograph.

**Storage:** Refrigerate (2 to 8° C) in original carton to protect from light. Do NOT freeze or shake. Keep out of the reach and sight of children.

**Non-medical ingredients:** L-histidine, L-histidine monohydrochloride, sucrose, L-methionine, and polysorbate and water for injection. Preservative free.

**SPECIFIC IMMUNOGLOBULIN:** Anti-SARS-CoV-2 IgG1 monoclonal antibody

DFT-03198-7757382

DIN 02518341

**Sotrovimab**

**for injection**

**500 mg / 8 mL**

**(62.5 mg / mL)**

**Solution for intravenous infusion**

Dilute before use.  
 Single-use vial. Discard unused portion.  
 For current Product Monograph, scan the QR code or visit [www.sotrovimabinfo.com](http://www.sotrovimabinfo.com).

LOT XXXXXXXX

EXP MM-YYYY

1 vial

Sterile

AREA FOR PRINTER COLOURS CONTROL

**Outer label**

DIN 02518341

**Pr Sotrovimab for injection**

**500 mg / 8 mL**

**(62.5 mg / mL)**

**Solution for intravenous infusion**

Dilute before use.

Single-use vial. Discard unused portion.

For current Product Monograph, scan the QR code or visit [www.sotrovimabinfo.com](http://www.sotrovimabinfo.com).

[QR code]

1 Vial

Sterile

SPECIFIC IMMUNOGLOBULIN: Anti-SARS-CoV-2 IgG1 monoclonal antibody

**Non-medicinal ingredients:** L-histidine, L-histidine monohydrochloride, sucrose, L-methionine, and polysorbate and water for injection. Preservative free.

**Storage:** Refrigerate (2 to 8° C) in original carton to protect from light. Do NOT freeze or shake. Keep out of the reach and sight of children.

**Dosage and administration:** See Product Monograph.

HEALTH CANADA HAS AUTHORIZED THE SALE OF THIS COVID-19 DRUG BASED ON LIMITED CLINICAL TESTING IN HUMANS AND/OR QUALITY INFORMATION

Questions / Concerns?

GlaxoSmithKline Inc.

Mississauga, Ontario L5N 6L4

[www.gsk.ca](http://www.gsk.ca)

LOT XXXXXXXXX

EXP MM-YYYY